FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397769881> ?p ?o ?g. }

• W2397769881 endingPage "218.e9" @default.
• W2397769881 startingPage "210" @default.
• W2397769881 abstract "BackgroundActivated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]–R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases.ObjectivesWe sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort.MethodsThe medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed.ResultsMutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications.ConclusionAPDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options. Activated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]–R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases. We sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort. The medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed. Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications. APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options." @default.
• W2397769881 created "2016-06-24" @default.
• W2397769881 creator A5000758355 @default.
• W2397769881 creator A5001888741 @default.
• W2397769881 creator A5003914408 @default.
• W2397769881 creator A5005130654 @default.
• W2397769881 creator A5006102363 @default.
• W2397769881 creator A5007387587 @default.
• W2397769881 creator A5013983797 @default.
• W2397769881 creator A5014546710 @default.
• W2397769881 creator A5014990865 @default.
• W2397769881 creator A5016522003 @default.
• W2397769881 creator A5016770644 @default.
• W2397769881 creator A5017789679 @default.
• W2397769881 creator A5018785043 @default.
• W2397769881 creator A5019327395 @default.
• W2397769881 creator A5025155115 @default.
• W2397769881 creator A5028131505 @default.
• W2397769881 creator A5028292912 @default.
• W2397769881 creator A5028703971 @default.
• W2397769881 creator A5029004287 @default.
• W2397769881 creator A5029262646 @default.
• W2397769881 creator A5029677894 @default.
• W2397769881 creator A5031636429 @default.
• W2397769881 creator A5032005250 @default.
• W2397769881 creator A5032303743 @default.
• W2397769881 creator A5032944606 @default.
• W2397769881 creator A5033994830 @default.
• W2397769881 creator A5045961328 @default.
• W2397769881 creator A5048770468 @default.
• W2397769881 creator A5048891191 @default.
• W2397769881 creator A5054926443 @default.
• W2397769881 creator A5056808342 @default.
• W2397769881 creator A5059539087 @default.
• W2397769881 creator A5063790935 @default.
• W2397769881 creator A5066970953 @default.
• W2397769881 creator A5069893143 @default.
• W2397769881 creator A5070905598 @default.
• W2397769881 creator A5071545468 @default.
• W2397769881 creator A5073718250 @default.
• W2397769881 creator A5077731556 @default.
• W2397769881 creator A5078377445 @default.
• W2397769881 creator A5081345270 @default.
• W2397769881 creator A5088473201 @default.
• W2397769881 creator A5090884203 @default.
• W2397769881 date "2016-07-01" @default.
• W2397769881 modified "2023-10-10" @default.
• W2397769881 title "Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study" @default.
• W2397769881 cites W1983226769 @default.
• W2397769881 cites W1995673950 @default.
• W2397769881 cites W2007074496 @default.
• W2397769881 cites W2011960178 @default.
• W2397769881 cites W2015782236 @default.
• W2397769881 cites W2055630249 @default.
• W2397769881 cites W2062089569 @default.
• W2397769881 cites W2072765132 @default.
• W2397769881 cites W2093262780 @default.
• W2397769881 cites W2094061741 @default.
• W2397769881 cites W2097665491 @default.
• W2397769881 cites W2108473200 @default.
• W2397769881 cites W2116879609 @default.
• W2397769881 cites W2120239952 @default.
• W2397769881 cites W2125260239 @default.
• W2397769881 cites W2143943364 @default.
• W2397769881 cites W2178214143 @default.
• W2397769881 cites W2213308312 @default.
• W2397769881 doi "https://doi.org/10.1016/j.jaci.2016.03.022" @default.
• W2397769881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27221134" @default.
• W2397769881 hasPublicationYear "2016" @default.
• W2397769881 type Work @default.
• W2397769881 sameAs 2397769881 @default.
• W2397769881 citedByCount "192" @default.
• W2397769881 countsByYear W23977698812016 @default.
• W2397769881 countsByYear W23977698812017 @default.
• W2397769881 countsByYear W23977698812018 @default.
• W2397769881 countsByYear W23977698812019 @default.
• W2397769881 countsByYear W23977698812020 @default.
• W2397769881 countsByYear W23977698812021 @default.
• W2397769881 countsByYear W23977698812022 @default.
• W2397769881 countsByYear W23977698812023 @default.
• W2397769881 crossrefType "journal-article" @default.
• W2397769881 hasAuthorship W2397769881A5000758355 @default.
• W2397769881 hasAuthorship W2397769881A5001888741 @default.
• W2397769881 hasAuthorship W2397769881A5003914408 @default.
• W2397769881 hasAuthorship W2397769881A5005130654 @default.
• W2397769881 hasAuthorship W2397769881A5006102363 @default.
• W2397769881 hasAuthorship W2397769881A5007387587 @default.
• W2397769881 hasAuthorship W2397769881A5013983797 @default.
• W2397769881 hasAuthorship W2397769881A5014546710 @default.
• W2397769881 hasAuthorship W2397769881A5014990865 @default.
• W2397769881 hasAuthorship W2397769881A5016522003 @default.
• W2397769881 hasAuthorship W2397769881A5016770644 @default.
• W2397769881 hasAuthorship W2397769881A5017789679 @default.
• W2397769881 hasAuthorship W2397769881A5018785043 @default.
• W2397769881 hasAuthorship W2397769881A5019327395 @default.
• W2397769881 hasAuthorship W2397769881A5025155115 @default.
• W2397769881 hasAuthorship W2397769881A5028131505 @default.
• W2397769881 hasAuthorship W2397769881A5028292912 @default.

• next